Demands of the association for disability rights and effective healthcare

 

Sarcoidosis is primarily a multisystem disease, which means that secondary diagnoses almost always accompany the primary diagnosis, whether they are suspected, differentially confirmed, or clinically proven.

This creates significant obstacles in disability assessment: hospital specialists often only assess the primary acute organ involvement, while disability assessment board doctors frequently lack expertise in the full systemic scope of the illness.

This gap in understanding stems from numerous uncertainties regarding the unpredictable activity and complex nature of this condition.

Specialists who are not fully familiar with systemic sarcoidosis tend to focus solely on acutely affected organs, overlooking secondary complications such as:

- Musculoskeletal issues affecting approximately 80% of patients (polyarthralgia, arthritis, soft tissue neuropathy, etc.);

- Vision complications in up to 20% of patients (retinal detachment, optic nerve lesions, uveitis, cataracts);

- Respiratory distress and related complications (pulmonary hypertension, Tietze syndrome);

- Cardiovascular alterations and arrhythmias;

- Psychophysical impairment (chronic fatigue, insomnia, loss of work capacity due to exhaustion, and impaired independent living).

Sarcoidosis has distinct stages and severity levels that are frequently omitted from specialist documentation.

Long-term treatment relies on cytostatics, corticosteroids, antimalarials, and strong analgesics, which themselves often exacerbate secondary health issues.

Due to healthcare system overloads, follow-up examinations are neither frequent nor standardized; vital routine checks like bone density scans and damage monitoring are frequently skipped.

Sarcoidosis triggers include exposure to Propionibacterium, viruses, molds, or environmental toxins in individuals with genetic predispositions, yet it is rarely recognized as such, lowering official disability evaluations.

There is a lack of qualitative assessment regarding patients' actual capacity for independent living and daily functionality.

Because clinical reports rarely capture a patient's overall daily performance, evaluating physicians and social workers lack a clear, objective picture of the individual's true state.

Sarcoidosis is characterized by intense fluctuations between good and bad days, which presents a major challenge for standard one-time evaluations.

Sarcoidosis is still not adequately listed on standard disability registries, leaving evaluations to subjective guesswork and analogies.

Lower limb complications affect around 80% of chronic patients, forcing many to rely on mobility aids or complete bed rest.

Virtually all patients suffer persistent disruptions in everyday life due to chronic fatigue, severe pain, and sudden bouts of malaise—factors that currently receive zero formal recognition in disability scoring.

The Sarcoidosis Association demands

- Inclusion of chronic sarcoidosis in the unified disability registry with disability grades III and IV, recognizing severe impairment, unyielding pain, persistent fatigue and occasional malaise, and long-term toxicity from corticosteroids, cytostatics, and antimalarials.

- A disability percentage reflecting reduced lower-limb mobility and loss of vision.

- Development of procedures for:

- Early diagnosis;

- Treatment;

- A multidisciplinary approach to documenting associated diagnoses, protecting health, improving timely access to treatment and supporting realistic disability assessment.

 

- Rights for people affected by sarcoidosis to reduced working hours and insurance service credited at an increased rate.

 

- Support from a social worker and psychological assistance to help patients cope with changed life circumstances (threats to life, reduced mobility, general exhaustion, threatened ability to work and job security, and financial insecurity due to loss of income during prolonged sick leave and treatment costs).

 

Dino-Josip Ključarić, Mag. Theol.
President of the Association

 

February 22, 2024

Rating: 0 stars, 0 votes.